Diathermy and balloon dilatation treatment of benign prostatic hypertrophy: a technology brief - nonsystematic review
Conseil d'Evaluation des Technologies de la Sante du Quebec
Record ID 31996008358
To review the current knowledge concerning the effectiveness, the safety and the costs of two new therapeutic approaches for the treatment of benign prostatic hypertrophy: balloon dilatation and diathermy, using either transrectal hyperthermia or transurethral thermotherapy.
Authors' results and conclusions:
Balloon dilatation is a simple, safe, low-cost procedure. It seems to be able to relieve the symptoms of prostatic obstruction. However, the limited number and the quality of the studies on the subject do not permit an evaluation of its effectiveness. It must therefore be considered as a technology in the "experimental" stage of its development.
Transrectal hyperthermia is a treatment which requires several sessions. Its use is limited because of the pain caused by temperature exceeding 44 C. Until now, it has not been shown that transrectal hyperthermia is able to bring significant and lasting reduction of the symptoms caused by prostatic obstruction.
Transurethral thermotherapy seems to be a more promising technology. In a single 60 minute session, the temperature of the prostate can be raised to "therapeutic" levels without anaesthesia. In some patients, this treatment can relieve the symptoms of prostatic obstruction with few side effects. Nevertheless, it has not yet been possible to establish the frequency, the degree, or the duration of the improvement in obstructive symptoms. Currently, this technology should therefore, be considered as being in the "experimental" stage and should only be performed as part of a research protocol.
English language abstract:
An English language summary is available
- Hyperthermia, Induced
- Prostatic Diseases
- Prostatic Hyperplasia
Conseil d'Evaluation des Technologies de la Santé du Québec
Conseil d'Evaluation des Technologies de la Santé du Québec, 2021, avenue Union, #1040, Montréal, Québec H3A S29, Canada. Tel: 514-873-2563; FAX: 514-873-1369
Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS)